SG47766A1 - CD2-binding domain of lymphocyte function associated antigen 3 - Google Patents

CD2-binding domain of lymphocyte function associated antigen 3

Info

Publication number
SG47766A1
SG47766A1 SG1996004272A SG1996004272A SG47766A1 SG 47766 A1 SG47766 A1 SG 47766A1 SG 1996004272 A SG1996004272 A SG 1996004272A SG 1996004272 A SG1996004272 A SG 1996004272A SG 47766 A1 SG47766 A1 SG 47766A1
Authority
SG
Singapore
Prior art keywords
binding domain
proteins
disclosed
those
associated antigen
Prior art date
Application number
SG1996004272A
Other languages
English (en)
Inventor
Barbara P Wallner
Glenn T Miller
Margaret D Rosa
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of SG47766A1 publication Critical patent/SG47766A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996004272A 1991-03-12 1992-03-12 CD2-binding domain of lymphocyte function associated antigen 3 SG47766A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66797191A 1991-03-12 1991-03-12
US77096791A 1991-10-07 1991-10-07

Publications (1)

Publication Number Publication Date
SG47766A1 true SG47766A1 (en) 1998-04-17

Family

ID=27099806

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004272A SG47766A1 (en) 1991-03-12 1992-03-12 CD2-binding domain of lymphocyte function associated antigen 3

Country Status (15)

Country Link
US (3) US5547853A (de)
EP (1) EP0503648B1 (de)
JP (3) JPH05508779A (de)
AT (1) ATE193724T1 (de)
AU (1) AU660981B2 (de)
CA (1) CA2081028C (de)
DE (1) DE69231135T2 (de)
DK (1) DK0503648T3 (de)
ES (1) ES2147178T3 (de)
GR (1) GR3034140T3 (de)
HK (1) HK1014030A1 (de)
HU (1) HU211476A9 (de)
PT (1) PT503648E (de)
SG (1) SG47766A1 (de)
WO (1) WO1992016622A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
DE69223638T2 (de) * 1991-10-07 1998-05-20 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
DE69232295T2 (de) * 1991-10-07 2002-07-18 Biogen Inc Verfahren zur Verbesserung der Toleranz für Allotransplantaten und Xenotransplantaten durch Verabreichung eines LFA-3- oder CD2-Bindungsproteins
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
JP2001511122A (ja) * 1997-01-10 2001-08-07 エピサイト ファーマシューティカル，インコーポレイテッド 新規な上皮組織標的化薬剤
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
PL346339A1 (en) * 1998-08-31 2002-02-11 Biogen Method of modulating memory effector t-cells and compositions
SI1109570T1 (sl) * 1998-08-31 2006-04-30 Biogen Idec Inc Modulacija spominskih efektorskih T-celic z vezavnim sredstvom CD2
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
EP1355919B1 (de) 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1419236A4 (de) * 2001-07-24 2005-08-03 Biogen Idec Inc Verfahren zur behandlung von sklerotischen erkrankungen unter verwendung cd2-bindender substanzen
EP1451558A1 (de) * 2001-11-28 2004-09-01 Graffinity Pharmaceuticals Aktiengesellschaft Spr-sensorflächenträger
DE10220593A1 (de) * 2001-11-28 2003-06-12 Graffinity Pharmaceuticals Ag SPR-Sensorflächenträger
WO2003046198A2 (de) * 2001-11-28 2003-06-05 Graffinity Pharmaceuticals Ag Verfahren zur selektion und identifikation von peptid- oder proteinmolekülen mittels phage display
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
EP1585546B1 (de) 2002-12-30 2008-08-06 Biogen Idec MA Inc. Kim-1-antagonisten und verwendung zur immunsystemmodulation
JP5452835B2 (ja) * 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるＩｇＭの産生とその定量方法
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
ATE518888T1 (de) * 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
WO2005112568A2 (en) * 2004-05-04 2005-12-01 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
US7662921B2 (en) * 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
MX2009004170A (es) * 2006-10-24 2009-06-26 Trubion Pharmaceuticals Inc Materiales y metodos para inmunoglicoproteinas mejoradas.
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2011156356A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
JP2014517685A (ja) 2011-04-15 2014-07-24 コンピュゲン エルティーディー． 免疫関連疾患およびがんの治療のためのポリペプチドおよびポリヌクレオチドならびにそれらの使用
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
ES2708699T3 (es) 2011-09-29 2019-04-10 Seattle Genetics Inc Determinación de la masa intacta de compuestos de agentes conjugados con proteínas
WO2014039983A1 (en) 2012-09-07 2014-03-13 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
JP6590810B2 (ja) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3185885B1 (de) 2014-08-26 2020-08-19 Compugen Ltd. Polypeptide und verwendungen davon als arzneimittel zur behandlung von autoimmunerkrankungen
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
DE3801511C2 (de) * 1988-01-20 1996-11-14 Espe Stiftung Verwendung von Photoinitiatoren zur Herstellung von in zwei Schritten härtbaren Dentalmassen
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
EP0345466A3 (de) * 1988-05-10 1991-04-17 EASTMAN KODAK COMPANY (a New Jersey corporation) Erzeugung von chimären Antikörpern in vivo durch ortsspezifische Rekombination
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990005144A1 (en) * 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
EP0451206A4 (en) * 1988-12-23 1992-07-22 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
JPH04506460A (ja) * 1990-01-26 1992-11-12 バイオジェン，インコーポレイテッド Ｃ４結合タンパク質の融合タンパク質
IL99864A (en) * 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens

Also Published As

Publication number Publication date
DE69231135D1 (de) 2000-07-13
US5728677A (en) 1998-03-17
US5914111A (en) 1999-06-22
AU1754092A (en) 1992-10-21
HU211476A9 (en) 1995-11-28
HK1014030A1 (en) 1999-09-17
JPH05508779A (ja) 1993-12-09
US5547853A (en) 1996-08-20
JP3520272B2 (ja) 2004-04-19
EP0503648A1 (de) 1992-09-16
PT503648E (pt) 2000-10-31
ES2147178T3 (es) 2000-09-01
WO1992016622A1 (en) 1992-10-01
CA2081028C (en) 1999-12-14
GR3034140T3 (en) 2000-11-30
DK0503648T3 (da) 2000-10-30
DE69231135T2 (de) 2001-02-15
JP2003089654A (ja) 2003-03-28
JP2002037800A (ja) 2002-02-06
AU660981B2 (en) 1995-07-13
EP0503648B1 (de) 2000-06-07
ATE193724T1 (de) 2000-06-15
CA2081028A1 (en) 1992-09-13

Similar Documents

Publication Publication Date Title
SG47766A1 (en) CD2-binding domain of lymphocyte function associated antigen 3
ZA91134B (en) New proteins produced by human lymphocytes,dna sequence encoding these proteins and their pharmaceutical and biological uses
EP1092774A3 (de) Borrelia burgdorferi Antigen OspA, dafür kodierendes Gen und ihre Verwendungen
MX9203138A (es) Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
EP0442961A4 (en) Hybrid procoagulant proteins
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP0849361A3 (de) Neue Liganden des Neuropeptide Rezeptors HFGAN72
AU7565991A (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
IL88293A0 (en) Alveolar surfactant proteins
CA2093659A1 (en) Dna sequence encoding bovine .alpha.-lactalbumin and methods of use
IL116559A0 (en) Chimeric proteins
GR3033328T3 (en) Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis.
EP0810285A3 (de) Mutanten von menschlichen Interleukin-3
HUT64369A (en) Collagen binding protein and method for producing it
GEP20043386B (en) β -Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same
EP0643133A3 (de) Rekombinante D-Hydantoinase, Verfahren zur Herstellung und Verwendung.
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
DE68914397D1 (de) Menschliches Lymphotoxin.
EP0315081A3 (en) Anti-coagulating protein pp4-x, its preparation and use
CA2004764A1 (en) Ancrod proteins, their preparation and use
DE69534738D1 (de) Leukocyten-aktivierender Faktor
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
AU1945592A (en) Human herpesvirus type 6 protein p100, the corresponding dna sequences, their preparation and use
MY134493A (en) Thrombopoietin peptides, fragments, nucleic acids encoding the same, and method